Meyka Pro banner
JPMorgan Short Duration Core Plus Fund Class A

Stay Updated with the Latest JPMorgan Short Duration Core Plus Fund Class A JSDHX News in Real Time

Find JSDHX news now at Meyka AI. Stay informed with the latest JPMorgan Short Duration Core Plus Fund Class A stocks updates, including price news, market analysis, and expert insights.

JSDHXNASDAQ
Financial ServicesAsset Management - Leveraged
$9.37
$0.010(0.11%)
U.S. Market opens in 7h 9m
AAPL Stock Rises 2.19% to $316.83 as Apple App Store Revenue Falls 18%
📅 in about 5 hours

AAPL Stock Rises 2.19% to $316.83 as Apple App Store Revenue Falls 18%

AAPL stock rose 2.19% to $316.83 on August 19, 2026, even as new data showed that Apple’s U.S. App Store commission revenue had fallen 18% since the start of the year. The move has caught investors’ attention because Apple continues to post strong results while facing pressure on its App Store business model. Services remain…

Read more 12
Gaja Alternative IPO GMP Today: How Gaja Capital Is Challenging the AIF Model
📅 in about 5 hours

Gaja Alternative IPO GMP Today: How Gaja Capital Is Challenging the AIF Model

Gaja Alternative IPO’s Grey Market Premium stood at ₹21 as of Thursday, August 20, 2026, 9:45 AM IST. That implies a listing price near ₹181, a 13% premium over the ₹160 upper band. The ₹550 crore issue from Gaja Capital’s asset management arm closes for subscription on August 21. Overall subscription remained modest at 0.30…

Read more 12
Former Hiroshima Teacher Sentenced to 9 Years for Abuse of 34 Girls
📅 in about 5 hours

Former Hiroshima Teacher Sentenced to 9 Years for Abuse of 34 Girls

Former Hiroshima elementary teacher sentenced to 9 years for indecent acts against 34 girls. Court ruling August 19, 2026.

Read more 12
Keio University Student Arrested for ¥1M Credit Card Fraud at Sports Facility
📅 in about 5 hours

Keio University Student Arrested for ¥1M Credit Card Fraud at Sports Facility

Keio University student arrested for ¥1M credit card fraud at Tokyo sports facility. Suspect allegedly used master key to access lockers and made small purchases to avoid PIN verification.

Read more 12
Crypto Tax Warning: HMRC Sent More Than 81,000 Letters to Cryptocurrency Holders
📅 in about 5 hours

Crypto Tax Warning: HMRC Sent More Than 81,000 Letters to Cryptocurrency Holders

HMRC has stepped up its focus on cryptocurrency taxes, with more than 81,000 warning letters reportedly sent to UK crypto holders during the 2025-26 tax year. The move comes as new crypto reporting rules take effect from January 1, 2026, giving HMRC greater access to user and transaction data. For investors, the message is clear:…

Read more 12
Social Security COLA 2027: New 3.6% Estimate Shows a Smaller Raise for Retirees
📅 in about 4 hours

Social Security COLA 2027: New 3.6% Estimate Shows a Smaller Raise for Retirees

The Social Security COLA for 2027 now stands at an estimated 3.6%, according to The Senior Citizens League. That’s down from 3.8% forecasts published in June and July. The drop follows July’s Consumer Price Index report, which showed inflation cooling to 3.4% year-over-year. Retirees would still see the largest benefit bump in four years if…

Read more 12
Moderna Soars 177% After Melanoma Vaccine Clears Phase 3 Trial on August 20
📅 in about 4 hours

Moderna Soars 177% After Melanoma Vaccine Clears Phase 3 Trial on August 20

Moderna stock jumped 177% after its melanoma vaccine met Phase 3 trial endpoints. The personalized mRNA therapy showed significant improvements over standard treatment in over 1,100 patients.

Read more 12
Nick Kyrgios Suspended After Testing Positive for Cocaine in Spain
📅 in about 3 hours

Nick Kyrgios Suspended After Testing Positive for Cocaine in Spain

Nick Kyrgios provisionally suspended after testing positive for cocaine metabolite at Mallorca ATP 250 event in June. The 31-year-old faces up to four-year ban but could receive reduced sanctions if drug use was out of competition.

Read more 12
Moderna Soars 177% on Melanoma Vaccine Win; August 20 Update
📅 in about 3 hours

Moderna Soars 177% on Melanoma Vaccine Win; August 20 Update

Moderna jumped 177% to $174.38 after Phase 3 melanoma vaccine trial success with Merck. The mRNA therapy reduced recurrence risk and represents the first approved late-stage cancer vaccine.

Read more 12

JSDHX News FAQ